Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of MenB vaccine and combined MenABCWY vaccine in healthy adolescents and young adults
2019-001666-15Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Meningococcal ABCWY, Multicomponent meningococcal B vaccine and meningococcal ACWY conjugate vaccine in meningococcal disease (3 arms), sponsored by GSK. Primary endpoint: Percentage of samples without bactericidal serum activity against endemic US serogroup B strains. Started Jul 2020; status: completed.
02
Drugs
Meningococcal ABCWYMulticomponent meningococcal B vaccinemeningococcal ACWY conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2019-001666-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001666-15.